Biocryst Pharmaceuticals (BCRX) EBIAT (2023 - 2025)
Biocryst Pharmaceuticals' EBIAT history spans 9 years, with the latest figure at $245.8 million for Q4 2025.
- For Q4 2025, EBIAT rose 1017.5% year-over-year to $245.8 million; the TTM value through Dec 2025 reached $263.9 million, up 396.87%, while the annual FY2025 figure was $263.9 million, 396.87% up from the prior year.
- EBIAT reached $245.8 million in Q4 2025 per BCRX's latest filing, up from $12.9 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $245.8 million in Q4 2025 to a low of -$201.7 million in Q4 2023.
- Average EBIAT over 3 years is -$3.0 million, with a median of -$12.7 million recorded in 2024.
- Peak YoY movement for EBIAT: surged 86.71% in 2024, then soared 1017.5% in 2025.
- A 3-year view of EBIAT shows it stood at -$201.7 million in 2023, then soared by 86.71% to -$26.8 million in 2024, then skyrocketed by 1017.5% to $245.8 million in 2025.
- Per Business Quant, the three most recent readings for BCRX's EBIAT are $245.8 million (Q4 2025), $12.9 million (Q3 2025), and $5.1 million (Q2 2025).